ACM
ITCI

Atika Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Atika Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-73,000
Closed -$6.1M – 104
2024
Q4 		$6.1M Sell
73,000
-10,000
-12% -$822K 0.65% 56
2024
Q3 		$6.07M Sell
83,000
-14,500
-15% -$1.09M 0.62% 50
2024
Q2 		$6.68M Sell
97,500
-7,500
-7% -$520K 0.65% 52
2024
Q1 		$7.27M Buy
105,000
+5,000
+5% +$344K 0.72% 54
2023
Q4 		$7.16M Buy
100,000
+14,100
+16% +$811K 0.96% 44
2023
Q3 		$4.47M Sell
85,900
-7,000
-8% -$408K 0.59% 57
2023
Q2 		$5.88M Buy
92,900
+39,900
+75% +$2.49M 0.59% 57
2023
Q1 		$2.87M Sell
53,000
-66,000
-55% -$3.19M 0.42% 60
2022
Q4 		$6.3M Sell
119,000
-44,900
-27% -$2.25M 0.91% 41
2022
Q3 		$7.63M Sell
163,900
-85,100
-34% -$4.45M 0.65% 60
2022
Q2 		$14.2M Buy
249,000
+39,000
+19% +$2.21M 1.6% 22
2022
Q1 		$12.8M Buy
+210,000
New +$10.9M 1.08% 38

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Atika Capital Management's ITCI Position: Q1 2025 in Review

Atika Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 73,000 shares — an estimated $6.1M sold.

Atika Capital Management first reported a position in ITCI in Q1 2022 and held it in 12 quarters. The position peaked at $14.2M in Q2 2022. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Atika Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Atika Capital Management sold 73,000 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $6.1M.
  • Atika Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 12 quarters.
  • Atika Capital Management's Intra-Cellular Therapies Inc. position peaked at $14.2M in Q2 2022.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Atika Capital Management's 13F filing for Q1 2025, filed 14 May 2025.